Pharmaceutical
The study, published in PLOS ONE, establishes LiquidHALLMARK’s market-leading sensitivity and identifies actionable biomarkers in majority of cancer patients and 70% of lung cancer patients; Mary Jo Mullen joins the Company as SVP, Commercial to oversee US market growth Excerpt from the Press Release: ALO ALTO, Calif.–(BUSINESS WIRE)–Lucence, the precision oncology company pioneering ultrasensitive liquid…
Read More
Excerpt from the Press Release: MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab’s targeting of IL-13Rα1 at…
Read More
Adding to previously reported overall functional and survival benefit data for AMX0035, these findings support effect of AMX0035 on disease progression in ALS Randomization to AMX0035 resulted in a lower occurrence of death or tracheostomy/permanent assisted ventilation by 49% and first hospitalization by 44% over the Phase 2 trial and duration of follow-up Excerpt from the Press…
Read More
CMS I-neb® is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease Breakthrough designation validates registrational path for CMS I-neb® in NCFB and facilitates potentially expedited development and review Excerpt from the Press Release: MILAN and BOSTON, April 21, 2022 /PRNewswire/ — Zambon, a…
Read More
Excerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel…
Read More
Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Excerpt from the Press Release: RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that The Lancet Neurology has publishedresults from the…
Read More- « Previous
- 1
- …
- 9
- 10
- 11